Pharma BD Deal Intelligence
Strong initial integration—J&J beat its own synergy targets folding in Listerine, Sudafed, Nicorette and Benadryl through 2008—but the $16.6B bet soured into a decade-long quality crisis at the shared McNeil manufacturing network, triggering mass recalls and eventual spin-off of the whole consumer unit.
Strong initial integration soured by a decade-long quality crisis, and the whole consumer unit was ultimately spun off into a stock that has underperformed
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
J&J's $16.6B acquisition of Pfizer's consumer health unit reflected drugmakers' search for secure revenue streams amid approaching patent expirations, though…
FTC required divestitures in OTC H-2 blockers (Zantac to Boehringer Ingelheim), hydrocortisone anti-itch, night-time sleep aids, and diaper rash treatments to…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Consumer health (Listerine, Nicorette, Sudafed, Benadryl, Neosporin); borderline - consumer/OTC scope; closed 2006-12-20
Strong initial integration soured by a decade-long quality crisis, and the whole consumer unit was ultimately spun off into a stock that has underperformed
Assessment window: 15yr post-close.
$3.9B Pfizer Consumer Healthcare 2005 revenue
The acquired Pfizer Consumer Healthcare business spanned five OTC franchises: oral care (Listerine antiseptic mouthwash), smoking cessation (Nicorette nicotine replacement), upper respiratory (Sudafed pseudoephedrine decongestant, Benadryl diphenhydramine antihistamine), topical anti-infective (Neosporin), and ophthalmic (Visine). Combined 2005 revenue was $3.9B across self-care/OTC categories serving tens of millions of US households annually.
Announced June 25, 2006 and closed December 20, 2006 for $16.6B in cash, the deal made J&J the world's #1 consumer health company by combining Pfizer Consumer Healthcare with J&J's existing Tylenol/Motrin/Band-Aid/Aveeno portfolio. The deal was an outcome of Pfizer's strategic decision to divest non-pharma businesses post-Pharmacia integration to refocus on prescription drugs. Competitive landscape included GlaxoSmithKline Consumer Healthcare (which itself bid against J&J before losing out), Bayer Consumer Care, Novartis OTC, Reckitt Benckiser, and Procter & Gamble's healthcare unit. The FTC required divestiture of Pfizer's Zantac H-2 blocker (sold to Boehringer Ingelheim), Cortizone hydrocortisone, Unisom sleep aid, and J&J's Balmex diaper rash treatment (sold to Chattem) to remedy overlaps in heartburn, anti-itch, sleep aid, and diaper rash OTC markets. Industry analysts framed the deal as defensive: facing patent cliffs, drugmakers were pulled toward stable consumer health revenue, but Pfizer's exit signaled the opposite strategic call. The combined J&J Consumer franchise later spun out as Kenvue in 2023.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Pfizer Consumer Healthcare (this deal) | 2006 | $16.6B | 56 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2006 deals · Johnson & Johnson deals · Multiple (undisclosed) deals